Cardioprotection of ( ±)-sodium 5-bromo-2-(α-hydroxypentyl) benzoate (BZP) on mouse myocardium I/R injury through inhibiting 12/15-LOX-2 activity

( ±)-Sodium5-bromo-2-(α-hydroxypentyl) benzoate (brand name: brozopine, BZP, 1a), derived from 1 to 3-n-Butylphthalide (NBP), has been reported to protect the brain from stoke and has been approved by CFDA in Phase I-II clinical trials. However, it remains to be investigated whether 1a may exhibit a ny cardioprotective effect on ischemia-reperfusion (I/R) injury. In the current study, C57BL/6 and ICR mice were pretreated with 1a, and myocardium I/R were then performed. We found that 1a not only significantly reduced the infarct size and improved cardiac contractile function after acute MI/R in both species, but also protected hearts from chronic MI-related cardiac injury.

Source: Journal of Molecular and Cellular Cardiology - July 26, 2019 Category: Cytology Authors: Yue Xiao, Chuanjun Song, Qiao Lin, Xiaojing Shi, Wenquan Yu, Xin Huang, Huimin Wang, Yang Chen, Ruiyong Wang, Xuepeng Geng, Mingyang Qin, Kaizhao Hu, Yilin Fan, Yan Qiao, Erhe Gao, Wen Zhao, Junbiao Chang Source Type: research